Disclosed herein are implantable devices coated with a reagent, and methods of preparing and utilizing such devices. The implantable device may comprise an implantable light conduit. The present disclosure enables a more precise registration between the reagent and the device implanted in the target tissue of a subject.

A hybrid molecule comprising at least one contrast agent, and at least one substrate of a self-labeling enzyme, and optionally a fluorescent moiety is provided. Compositions comprising same and use thereof, are also provided.

Described herein are compounds, compositions and methods for modification of the surface of a living cell with a therapeutically relevant targeting moiety. Also described herein are methods for treating disease states, such as acute myocardial ischemia or infarction, with said compositions, in a subject.

Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system.

A method for manufacturing bubbles of the present invention includes: injecting an aqueous liquid 10 into a container 20 to a predetermined height; and vibrating the container at the number of revolution of equal to or high than 5,000 rpm such that the aqueous liquid 10 repeatedly collides with an inner surface of the container 20. According to the manufacturing, simply by vibrating the container 20 at a predetermined number of revolution, a large amount of bubbles 1 having a uniform size can be stably generated in the aqueous liquid 10. Furthermore, the vibrating the container 20 is preferably performed in a state where an internal pressure of the container 20 is higher than 1.0 atm.

Disclosed are compounds of formula (I) below:

##STR00001## wherein each of the variables A, B, X, W, V, R.sub.1-R.sub.5, and m are defined herein. Also disclosed are pharmaceutical compositions containing a nanocomplex, wherein the nanocomplex is formed of one of the compounds, and a protein, a nucleic acid, or a small molecule; and methods of treating a medical condition with one of the pharmaceutical compositions.

The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets. The method of treatment is performed and then, depending upon the desired clinical outcome, repeated after a treatment response interval has elapsed.

Disclosed herein are compounds having activity as cell penetrating peptides. In some examples, the compounds can comprise a cell penetrating peptide moiety and a cargo moiety. The cargo moiety can comprise one or more detectable moieties, one or more therapeutic moieties, one or more targeting moieties, or any combination thereof. In some examples, the cell penetrating peptide moiety is cyclic. In some examples, the cell penetrating peptide moiety and cargo moiety together are cyclic. In some examples, the cell penetrating peptide moiety is cyclic and the cargo moiety is appended to the cyclic cell penetrating peptide moiety structure. In some examples, the cargo moiety is cyclic and the cell penetrating peptide moiety is cyclic, and together they form a fused bicyclic system.

The present disclosure provides nucleic acid activity-dependent expression vectors and activity-dependent expression cassettes for the activity-dependent expression of an encoded polypeptide. Also provided are recombinant adenoassociated viruses (AAV) containing an expression vector comprising an activity-dependent expression cassette for the activity-dependent expression of an encoded polypeptide by cells infected with the AAV vector. The present disclosure also provides methods for the activity-dependent labeling of cells in vitro or in vivo by introducing into the cells an expression vector containing an activity-dependent regulatory sequence driving expression of a labeling polypeptide. Also provided are methods for the activity-dependent control of cells in vitro or in vivo by introducing into the cells an expression vector containing an activity-dependent regulatory sequence driving expression of a light-responsive polypeptide.

Disclosed are a human-derived ferritin monomer fragment and a fusion polypeptide using the same, and more particularly, to a human-derived ferritin of which a portion of a fourth loop and a fifth helix of the ferritin monomer fragment are removed, and a fusion polypeptide in which a polypeptide or a protein is fused to an N-terminus or a C-terminus of the ferritin monomer fragment.